Drgem디알젬

Drgem is a small X-ray equipment maker whose profits have shrunk since 2022, while its shares sit near the low end of their 52-week range.

Drgem makes diagnostic X-ray imaging equipment and components, selling through about 250 dealers in roughly 120 countries. Trailing twelve-month revenue to H1 2026 was ₩109B and net income was ₩12B, with operating margin at 9.7%. Revenue fell 1.2% in 2025 and the shares are down 17% over the past year, closing at ₩4,905.

What stands out

• Revenue has been broadly flat, at about ₩103B in 2025 versus ₩110B in 2022, while operating income fell from ₩17B to ₩9B over the same period.
• Trailing net income of ₩12B is above operating income, so non-operating items or other factors contributed; the data does not explain the difference.
• The balance sheet looks modest: liabilities are 34.2% of equity, cash is ₩14.5B against borrowings of ₩10B, and trailing free cash flow is ₩8.8B.
• Valuation metrics are low, with a P/E of 4.5 and P/B of 0.6, and a 3.6% dividend yield, but the data does not include analyst targets.
• A major sales or supply contract was filed on 2026-07-22, though its size and terms are not in the data.

What to watch

• The H1 2026 half-year report was filed on 2026-08-14; the data does not include its detailed figures, so check the filing for segment and margin trends.
• Foreign ownership rose slightly to 15.8% and retail investors were net sellers over the last 20 days, so monitor whether these flows persist.
• The DCF fair value range is ₩6,951 to ₩18,658 with a base of ₩11,239, but this is a model output rather than a forecast; the company's sales outlook and any future contract disclosures are not in the data.